Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-12-22

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for a buprenorphine and naloxone product from Sun Pharmaceutical Industries, Inc., signifying approval of a generic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)